269 related articles for article (PubMed ID: 35194144)
1. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
Commun Biol; 2022 Feb; 5(1):154. PubMed ID: 35194144
[TBL] [Abstract][Full Text] [Related]
2. Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.
Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
bioRxiv; 2021 Jul; ():. PubMed ID: 34312622
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
4. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
5. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
6. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
Scholle MD; Liu C; Deval J; Gurard-Levin ZA
SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
[TBL] [Abstract][Full Text] [Related]
7. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185
[TBL] [Abstract][Full Text] [Related]
9. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
[TBL] [Abstract][Full Text] [Related]
10. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
11. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N; Nair DT
Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
[TBL] [Abstract][Full Text] [Related]
13. [RNA polymerase: The Achilles heel of SARS-CoV-2].
Corteggiani M; Gombert L; Pellegri C; Aussel L
Med Sci (Paris); 2021 Mar; 37(3):288-292. PubMed ID: 33739278
[No Abstract] [Full Text] [Related]
14. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
15. An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex.
Shannon A; Chazot A; Feracci M; Falcou C; Fattorini V; Selisko B; Good S; Moussa A; Sommadossi JP; Ferron F; Alvarez K; Canard B
Nucleic Acids Res; 2024 Feb; 52(3):1325-1340. PubMed ID: 38096103
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
[TBL] [Abstract][Full Text] [Related]
17. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro.
Boccuto A; Dragoni F; Picarazzi F; Lai A; Della Ventura C; Veo C; Giammarino F; Saladini F; Zehender G; Zazzi M; Mori M; Vicenti I
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800884
[TBL] [Abstract][Full Text] [Related]
19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
20. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
